therascreen KRAS Assay Package CE

therascreen KRAS Assay Package CE — QIAGEN therascreen assay for qualitative detection of clinically relevant KRAS mutations in DNA from tumor specimens. CE‑marked IVD intended to support molecular oncology testing; supplied with controls and instructions for use. Optimized for use with compatible real‑time PCR platforms and laboratory workflows.